Origins in Hong Kong
Hong Kong, underpinned by the motherland and connected to global markets, has played a pioneering role in pioneering China's civilian nuclear industry.
English
- English
- 中文
Pamedic | Company Profile
PanMediso | Company Profile
WHO WE ARE
Pamedic is a globally integrated enterprise dedicated to innovation across the entire nuclear medicine ecosystem—spanning industry, academia, research, diagnostics, and therapy. We bring together world-leading expertise in radioisotope technology to develop and manufacture cutting-edge medical isotopes such as Ac-225 and Ge-68.
With plans to expand into new application areas, Pamedic provides end-to-end solutions, from raw materials to finished products, and from R&D to scale-up and commercial cGMP production, for the development of radiopharmaceuticals. The company is building a comprehensive technology platform encompassing isotope production, core equipment R&D, nuclear medicine CXO services, next-generation diagnostic systems, and AI-enhanced theragnostic applications.
Through strategic global partnerships, Pamedic is committed to accelerating the growth of the nuclear medicine industry, contributing to scientific advancement and improved human health worldwide.
ABOUT US
PanMediso is a globally integrated enterprise dedicated to innovation across the entire nuclear medicine ecosystem—spanning industry, academia, research, diagnostics, and therapy. We bring together world-leading expertise in radioisotope technology to develop and manufacture cutting-edge medical isotopes such as Ac-225 and Ge-68.
With plans to expand into new application areas, PanMediso provides end-to-end solutions, from raw materials to finished products, and from R&D to scale-up and commercial cGMP production, for the development of radiopharmaceuticals. The company is building a comprehensive technology platform encompassing isotope production, core equipment R&D, nuclear medicine CXO services, next-generation diagnostic systems, and AI-enhanced theragnostic applications.
Through strategic global partnerships, PanMediso is committed to accelerating the growth of the nuclear medicine industry, contributing to scientific advancement and improved human health worldwide.
OUR JOURNERY
PanMediso has evolved through four strategic phases of global growth: beginning with foundational projects in Hong Kong, establishing technological capabilities in the UK through collaboration with Canadian Nuclear Laboratories, expanding into Shenzhen with a dual-headquarters model, and achieving breakthroughs in α-radionuclide therapeutics. With R&D originating from our UK laboratory and the establishment of raw material production bases in both China and the UK, we are now positioned to overcome critical supply chain challenges in the domestic nuclear medicine sector. As an integrated international enterprise, PanMediso is committed to end-to-end development, manufacturing, and global commercialization of innovative radiopharmaceuticals,from radionuclides and ligands to finished drugs,driving a new era of targeted cancer therapy worldwide.
OUR JOURNERY
Pamedic has evolved through four strategic phases of global growth: beginning with foundational projects in Hong Kong, establishing technological capabilities in the UK through collaboration with Canadian Nuclear Laboratories, expanding into Shenzhen with a dual-headquarters model, and achieving breakthroughs in α-radionuclide therapeutics. With R&D originating from our UK laboratory and the establishment of raw material production bases in both China and the UK, we are now positioned to overcome critical supply chain challenges in the domestic nuclear medicine sector. As an integrated international enterprise, PanMediso is committed to end-to-end development, manufacturing, and global commercialization of innovative radiopharmaceuticals,from radionuclides and ligands to finished drugs,driving a new era of targeted cancer therapy worldwide.
Hong Kong
the UK
Foundation in the UK
The Liverpool team in the UK has driven core technological breakthroughs, established raw material production capabilities, and developed a dedicated R&D base, forming a critical foundation for PanMediso's global operations.
Shenzhen
Headquarter in Shenzhen
PanMediso established its Shenzhen headquarter as a strategic hub for integrated nuclear medicine innovation, combining global research excellence with advanced manufacturing and clinical translation capabilities to drive the development of next-generation radiopharmaceuticals.
China
Domestic Technological Breakthrough
Committed to the localization and scaling of core technologies, PanMediso has pioneered transformative advances in nuclear medicine—establishing China’s first fully integrated capabilities in radioisotope production and radiopharmaceutical development and ending long-standing import dependencies.
Worldwide
Global Expansion and Growth
PanMediso is accelerating growth through nationwide business scaling and strategic partnerships with leading international companies, enhancing its global supply chain and expanding access to next-generation radiopharmaceuticals worldwide.
Email: pchl@pamedicholdings.com
Address: Room 406, Building C, Hetao Innovation Center No. 1 Honghua
Road, Fubao Subdistrict Futian District, Shenzhen, China
Copyright@2025 PanMediso
